Abide Therapeutics, Inc.San Diego, CA

Abide Therapeutics, Inc. will exploit the vast therapeutic potential of serine hydrolases. The broad platform has the potential to treat various indications such as central nervous system disorders, ovarian cancer, diabetes, viruses, bacteria and orphan diseases.

 

Momenta Pharmaceuticals (MNTA)Cambridge, MA

Drug discovery based on glycomics, (the study of complex sugars) Groundbreaking application in the area of developing generic biologics. CHP II was founding investor, June 2004 IPO. Co-Investors: Polaris, Atlas, MVM, Mithra.

Alnylam Pharmaceuticals (ALNY)Cambridge, MA

Drug discovery, based on RNAi (RNA interference or 'short interfering RNA); a discovery that enables the creation of a broad new class of human therapeutics. CHPII was founding investor, IPO in 2004.

 

Rib-X PharmaceuticalsNew Haven, CT

Small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. CHP II was series A investor. Development stage.

aTyr Pharma, Inc.San Diego, CA

Biopharmaceutical company focused on identifying and developing a novel class of naturally occurring protein biologics for therapeutic application. CHP III was initial investor, incubated at Cardinal. Development stage.

 

Sirtris Pharmaceuticals (ex SIRT)Boston, MA

Biopharmaceutical research based on research associated with sirtuin enzymes, with eventual application in diseases associated with aging, such as Type 2 Diabetes. In humans. IPO in 2006, acquired by GSK in 2007. CHP II was founding investor.

Cubist Pharmaceuticals, Inc. (CBST)Cambridge, MA

Novel anti-infectives: CUBICIN (daptomycin for injection) was the first IV antibiotic from a class of antiinfectives known as lipopeptides. DSV IV (CHP predecessor) incubated company, CHP I invested in PIPE round.

 

VerastemBoston, MA

Novel drug development company targeting cancer stem cells.